Importantly, we have shown that GLS silencing and inhibition in vivo by using molecular approaches specifically targeting the liver can attenuate NASH both by reducing the accumulation of lipids and reactive oxygen species (ROS) in pre-clinical animal models of methionine and/or choline restricted diets-induced NASH [2]. The gene discussed is GLS; the disease is metabolic dysfunction-associated steatohepatitis.